Predictive factors for the benefit of triple‐drug transarterial chemoembolization for patients with unresectable hepatocellular carcinoma

BACKGROUND: Compared with single‐drug TACE, our previous phase III study demonstrated that triple‐drug transarterial chemoembolization (TACE) prolonged overall survival (OS) in patients with unresectable hepatocellular carcinoma (HCC). The aim of this study was to find which patients can benefit fro...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Med
Autors principals: He, MinKe, Li, Qing, Shen, JingXian, Tan, GuoSheng, Li, QiJiong, Lai, JiaYing, Wei, Wei, Zhang, YaoJun, Zou, RuHai, Chen, MinShan, Guo, RongPing, Shi, Ming
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2019
Matèries:
Clinical Cancer Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6675716/
https://ncbi.nlm.nih.gov/pubmed/31207163
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.2355
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars